[Long-term results of radiotherapy for malignant tumors of the nasal cavity--report on 317 patients].
From 1964 to 1982, 317 patients with malignant tumors of the nasal cavity were treated by radiotherapy. All had been proved pathologically prior to treatment. The over-all 5- and 10-year survival rates were 42.6% and 32.7%. Those of T1N0 lesions were 64.3% and 54.3%. Patients with submaxillary metastasis gave 5- and 10-year survivals of 35.3% and 26.9% while those with regional lymph node metastasis in the neck gave 26.9% and 15.8%, respectively. The results of orthovoltage X-rays treatment were not inferior to those of telecobalt. Pathologic classification and the radiation dose given bore no weight on survival. The major sequelae were nose bleeding (due to mucosal atrophy), deformity, atrophy or perforation of septum. 57.1% of death was attributed to local progression or recurrence while 32.5% due to distant metastasis. 72% of death occurred within 2 years of treatment.
Mao
Z D
ZD
Cancer Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, Guangdong.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D002648:Child; D002675:Child, Preschool; D003037:Cobalt Radioisotopes; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011867:Radioisotope Teletherapy; D012509:Sarcoma / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D015996:Survival Rate
D003037:Cobalt Radioisotopes